Clinical pharmacology of caplacizumab for the treatment of patients with acquired thrombotic thrombocytopenic purpura-Reference-Cited by-同舟云学术

Clinical pharmacology of caplacizumab for the treatment of patients with acquired thrombotic thrombocytopenic purpura

Published:2019-04-28 Issue:6 Volume:12 Page:537-545
ISSN:1751-2433
Container-title:Expert Review of Clinical Pharmacology
language:en
Short-container-title:Expert Review of Clinical Pharmacology

Author:

Sargentini-Maier Maria Laura¹,De Decker Philip²,Tersteeg Claudia³,Canvin Jan⁴,Callewaert Filip⁵,De Winter Hilde⁶

Affiliation:

1. Clinical Development, Ablynx, a Sanofi company, Zwijnaarde, Belgium

2. Pharmacology, Ablynx, a Sanofi company, Zwijnaarde, Belgium

3. Formerly Pharmacology, Ablynx NV, Zwijnaarde, Belgium

4. Medical Safety Evaluation, Sanofi, Guilford, UK

5. Medical Affairs, Sanofi, Diegem, Belgium

6. Formerly Clinical Development, Ablynx NV, Ghent, Belgium

Funder

was not funded

Publisher

Informa UK Limited

Subject

Pharmacology (medical),General Pharmacology, Toxicology and Pharmaceutics,General Medicine

Link

https://tandfonline.com/doi/pdf/10.1080/17512433.2019.1607293

Reference44 articles.

1. Regional UK TTP Registry: correlation with laboratory ADAMTS 13 analysis and clinical features

2. Rajan SK Thrombotic thrombocytopenic purpura. BMJ best practice topics. 2017. [cited 2019 Apr]. Available from: https://bestpractice.bmj.com/topics/en-gb/715

3. Children and adults with thrombotic thrombocytopenic purpura associated with severe, acquired Adamts13 deficiency: Comparison of incidence, demographic and clinical features

4. Antibodies to von Willebrand Factor–Cleaving Protease in Acute Thrombotic Thrombocytopenic Purpura

5. Thrombotic Thrombocytopenic Purpura: The Systemic Clumping “Plague”

Cited by 49 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Frontline use of rituximab may prevent ADAMTS13 inhibitor boosting during caplacizumab treatment in patients with iTTP: post hoc analysis of a phase 2/3 study in Japan;Thrombosis Journal;2024-08-02

2. Non-invasive strategy: Developing a topical IL-4Rα-specific nanobody for the treatment of allergic airway diseases;Materials Today Bio;2024-08

3. Single-Domain Antibodies—Novel Tools to Study and Treat Allergies;International Journal of Molecular Sciences;2024-07-11

4. Caplacizumab improves clinical outcomes and is well tolerated across clinically relevant subgroups of patients with immune-mediated thrombotic thrombocytopenic purpura;Research and Practice in Thrombosis and Haemostasis;2024-07

5. Iatrogenic hemorrhage and extensive venous thromboembolism during iTTP treatment with caplacizumab—A case report;eJHaem;2024-06-10